GYKI-14451 sulfate | CAS#83861-29-4 | 69201-89-4 | thrombin inhibitor

MedKoo Cat#: 526603 | Name: GYKI-14451 sulfate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

GYKI-14451, also known as LY-178207, is a synthetic tripeptide inhibitor of thrombin with anti-atherosclerotic activity.

Chemical Structure

GYKI-14451 sulfate

CAS#83861-29-4 (sulfate)

Theoretical Analysis

MedKoo Cat#: 526603

Name: GYKI-14451 sulfate

CAS#: 83861-29-4 (sulfate)

Chemical Formula: C50H78N12O14S

Exact Mass:

Molecular Weight: 1103.30

Elemental Analysis: C, 54.43; H, 7.13; N, 15.23; O, 20.30; S, 2.91

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

83861-29-4 (sulfate) 69201-89-4 (free base)

Synonym

GYKI-14451; GYKI 14451; GYKI14451; GYKI-14,451; GYKI 14,451; GYKI14,451; LY-178207; LY178207; LY 178207; Boc-D-Phe-Pro-Arg-H.

IUPAC/Chemical Name

tert-butyl ((R)-1-((S)-2-(((S)-5-guanidino-1-oxopentan-2-yl)carbamoyl)pyrrolidin-1-yl)-1-oxo-3-phenylpropan-2-yl)carbamate hemisulfate

InChi Key

QTXYFTMWQXMAQW-DCBJEQAZSA-N

InChi Code

InChI=1S/2C25H38N6O5.H2O4S/c2*1-25(2,3)36-24(35)30-19(15-17-9-5-4-6-10-17)22(34)31-14-8-12-20(31)21(33)29-18(16-32)11-7-13-28-23(26)27;1-5(2,3)4/h2*4-6,9-10,16,18-20H,7-8,11-15H2,1-3H3,(H,29,33)(H,30,35)(H4,26,27,28);(H2,1,2,3,4)/t2*18-,19+,20-;/m00./s1

SMILES Code

O=C(N[C@H](C=O)CCCNC(N)=N)[C@H]1N(C([C@@H](CC2=CC=CC=C2)NC(OC(C)(C)C)=O)=O)CCC1.O=C(N[C@H](C=O)CCCNC(N)=N)[C@H]3N(C([C@@H](CC4=CC=CC=C4)NC(OC(C)(C)C)=O)=O)CCC3.O=S(O)(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,103.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Callas DD, Fareed J. Direct inhibition of protein Ca by site directed thrombin inhibitors: implications in anticoagulant and thrombolytic therapy. Thromb Res. 1995 Jun 1;78(5):457-60. PubMed PMID: 7544924. 2: Callas D, Iqbal O, Fareed J. Comparison of the anticoagulant activities of thrombin inhibitors as assessed by thromboelastographic analysis. Semin Thromb Hemost. 1995;21 Suppl 4:76-9. PubMed PMID: 8747693. 3: Callas D, Bacher P, Iqbal O, Hoppensteadt D, Fareed J. Fibrinolytic compromise by simultaneous administration of site-directed inhibitors of thrombin. Thromb Res. 1994 May 1;74(3):193-205. PubMed PMID: 8042188. 4: Barabas E, Szell E, Bajusz S. Screening for fibrinolysis inhibitory effect of synthetic thrombin inhibitors. Blood Coagul Fibrinolysis. 1993 Apr;4(2):243-8. PubMed PMID: 8499562. 5: Jackson CV, Wilson HC, Growe VG, Shuman RT, Gesellchen PD. Reversible tripeptide thrombin inhibitors as adjunctive agents to coronary thrombolysis: a comparison with heparin in a canine model of coronary artery thrombosis. J Cardiovasc Pharmacol. 1993 Apr;21(4):587-94. PubMed PMID: 7681904. 6: Bagdy D, Barabás E, Bajusz S, Széll E. In vitro inhibition of blood coagulation by tripeptide aldehydes--a retrospective screening study focused on the stable D-MePhe-Pro-Arg-H.H2SO4. Thromb Haemost. 1992 Mar 2;67(3):325-30. PubMed PMID: 1641823. 7: Bajusz S, Szell E, Bagdy D, Barabas E, Horvath G, Dioszegi M, Fittler Z, Szabo G, Juhasz A, Tomori E, et al. Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative, D-MePhe-Pro-Arg-H. J Med Chem. 1990 Jun;33(6):1729-35. PubMed PMID: 2342067. 8: Witting JI, Pouliott C, Catalfamo JL, Fareed J, Fenton JW 2nd. Thrombin inhibition with dipeptidyl argininals. Thromb Res. 1988 May 15;50(4):461-7. PubMed PMID: 3413714. 9: Makara GB, Szentendrei T, Rappay G. Is calcium or cyclic AMP involved in the inhibitory effect on pituitary hormone secretion of the tripeptide aldehyde proteinase inhibitors? Mol Cell Endocrinol. 1987 Jul;52(1-2):63-9. PubMed PMID: 2442048. 10: Rappay G, Fazekas I, Bácsy E, Gaál G, Stoeckel ME, Nagy I, Gyévai A, Makara GB. Proteinase inhibitors while influencing hormone release do not affect cell morphology of hypophyseal cultures. Acta Morphol Hung. 1987;35(3-4):145-56. PubMed PMID: 3137779. 11: Fazekas I, Rappay G, Bácsy E, Medzihradszky-Schweiger H, Gyévai A, Gaál G. Dissimilar responsiveness of cultured corticotrophs and melanotrophs to tripeptide aldehydes. Histochemistry. 1986;84(4-6):418-22. PubMed PMID: 3013810. 12: Nagy I, Makara GB, Horváth G, Rappay G, Kurcz M, Bajusz S. Tripeptide aldehyde protease inhibitors may depress in vitro prolactin and growth hormone release. Endocrinology. 1985 Apr;116(4):1426-32. PubMed PMID: 3971921. 13: Tremoli E, Colli S, Paoletti R. GYKI 14,451, a synthetic tripeptide inhibitor of thrombin: "in vitro" and "in vivo" studies. Adv Exp Med Biol. 1984;164:187-92. PubMed PMID: 6695572. 14: Barna I, Gráf L, Makara GB, Rappay G. A serine-proteinase inhibitor (Boc-D-Phe-Pro-Arg-H) inhibits the secretion of adrenocorticotropin- and beta-endorphin-immunoreactive peptides in vitro. Neuropeptides. 1982 Oct;3(1):65-70. PubMed PMID: 6296720. 15: Bajusz S, Széll E, Barabás E, Bagdy D. Design and synthesis of peptide inhibitors of blood coagulations. Folia Haematol Int Mag Klin Morphol Blutforsch. 1982;109(1):16-21. PubMed PMID: 6177598. 16: Tremoli E, Morazzoni G, Maderna P, Colli S, Paoletti R. Studies on the antithrombotic action of Boc-D-Phe-Pro-Arg-H (Gyki 14,451). Thromb Res. 1981 Sep 15;23(6):549-53. PubMed PMID: 7324011. 17: Tremoli E, Maderna P, Colli S, Agradi E, Petroni A, Paoletti R. GYKI 14,451, a synthetic tripeptide inhibitor of thrombin: activity on platelet aggregation and arachidonic acid metabolism. Pharmacol Res Commun. 1981 Apr;13(4):339-49. PubMed PMID: 7291273. 18: Sirtori CR, Tremoli E, Paoletti R. New strategies in the development of anti-atherosclerotic drugs. Artery. 1980;8(6):507-18. Review. PubMed PMID: 7020650.